RxDoctor Payments Data

Tetsoma Tonwe, MD

Family Medicine · Milford, DENPI 1629431267

Payments from drug & device makers

$302in general payments, 2019–2025

Across 12 payments — averaging $25.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Idorsia Pharmaceuticals US Inc$110
  • Novo Nordisk$72
  • Dexcom, Inc.$40
  • AbbVie$26
  • Pfizer$24
  • Neurocrine Biosciences, Inc.$21
  • plus $8 from 1 others

What the payments were for

  • Food & beverage$302100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$302 in reported general payments places this provider in the 45th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$77,662
Medicare patients
87
Services billed
978

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$84,169
MounjaroTirzepatide53$57,120
LinzessLinaclotide71$51,909
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$47,850
WegovySemaglutide16$21,918
TrulicityDulaglutide19$21,483
RybelsusSemaglutide20$20,471
FarxigaDapagliflozin Propanediol33$19,645
MovantikNaloxegol Oxalate33$19,456
EliquisApixaban17$18,045
BelbucaBuprenorphine Hcl12$11,234
BelsomraSuvorexant17$10,762
RestasisCyclosporine14$9,095
EntrestoSacubitril/Valsartan13$7,910
ValiumDiazepam12$7,369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy, Rybelsus$72$126,558107 claims
AbbVieLinzess, Restasis, Synthroid$26$62,850100 claims
PfizerEliquis$24$18,04517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 352 family medicine providers in Delaware.

Other family medicine in Milford

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →